Loading
Old version — revision 1
This is a fixed snapshot of Alcor Life Extension Foundation, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/alcor.md — the filesystem corpus, unchanged. Not an edit.
A United States cryonics organization, founded in 1972, that preserves legally dead members at cryogenic temperatures under a trust structure meant to fund storage indefinitely.
Alcor Life Extension Foundation is a nonprofit organization in Scottsdale, Arizona that performs and maintains human cryopreservation. Founded in California in 1972, it is among the largest such organizations by number of patients in storage and has done more than most to formalize the practice — standby teams, vitrification protocols, and a segregated trust intended to fund liquid nitrogen indefinitely. It makes no claim that revival is currently possible, and its own literature describes the arrangement as a bet.
Alcor's function is administrative as much as technical. Preservation must begin immediately after a physician pronounces death, which requires knowing when a member is dying, having people and equipment in place, and having a legal instrument that survives family objection. The organization's procedures are built around that timing problem, and its documented failures have generally been failures of logistics rather than of cryobiology.
The rule cuts the other way as well: nothing may be done before pronouncement, which guarantees an interval of warm ischemia and rules out preserving a member whose brain is being destroyed by a progressive disease while they remain legally alive. That constraint sits awkwardly beside assisted-dying law and has been challenged unsuccessfully in court.
Members sign a contract and fund it, most commonly by naming Alcor as beneficiary of a life insurance policy, which converts a large capital cost into a manageable premium and makes the arrangement cheap for the already insurable — one narrow instance of the Access and inequality problem that runs through life-extension technology. On death, a standby team stabilizes the body, perfusion with cryoprotectant is performed at the Scottsdale facility, and the patient is cooled to liquid nitrogen temperature and stored in a dewar. Two options exist: whole-body preservation, and neuropreservation of the head alone, on the reasoning that any technology capable of revival could also supply a body. That reasoning leans on Lab-grown organs and on Whole brain emulation as the alternative routes to a functioning person.
Fred and Linda Chamberlain founded the organization in 1972 as the Alcor Society for Solid State Hypothermia, taking the name from a star in Ursa Major. It performed its first cryopreservation in 1976. The organization relocated from California to Scottsdale in 1994, partly for seismic and regulatory reasons.
Alcor also holds James Bedford, the first person ever cryopreserved, in 1967. His body was maintained privately by his family for decades and transferred to Alcor in 1991, where an inspection found the preservation had held despite decades of unstandardized storage.
Alcor's operational sequence has three phases, and the first is where most of the variance lies.
Standby and stabilization. For a member dying in a hospital or hospice with warning, a team deploys in advance. After pronouncement, circulation is restored mechanically, cooling begins with ice, and drugs intended to limit reperfusion injury and clotting are administered. For an unwitnessed death, none of this happens, and warm ischemia proceeds for hours or days. The difference between the best and worst case is the single largest determinant of preservation quality, and Alcor's own case reports say so.
Cryoprotective perfusion. Blood is replaced by a vitrification solution, ramped up in concentration over hours. Alcor uses solutions of the class developed at 21st Century Medicine, engineered to suppress ice at concentrations that are less toxic than earlier formulations. Perfusion quality is assessed by measures including cryoprotectant concentration in venous return and, for neuro cases, by observation of the brain surface.
Cooldown and storage. Patients are cooled below the glass transition and then to −196 °C and stored inverted in dewars of liquid nitrogen, so that a failure of resupply exposes the feet before the head. Cooling below the glass transition produces thermal stress and fracturing, a documented and unresolved problem; intermediate-temperature storage has been discussed as a remedy and is more complex to maintain.
What Alcor does not claimThe organization does not assert that its patients can be revived, that current methods preserve a person intact, or that any timeline exists. Its published position is that preservation is worth attempting because the alternative is certain, and because information may survive that present medicine cannot use. Cryobiology societies do not accept even this weaker claim as established.
Dora Kent (1987). Kent, the mother of an Alcor member, was neuropreserved shortly after her death at the Alcor facility. The Riverside County coroner concluded that barbiturates had been administered before death and issued a homicide finding; the facility was raided, staff were detained, and the organization fought the case for years. No charges were ultimately brought, and courts found substantially in Alcor's favour. The episode established, in practice, that the organization would litigate.
Ted Williams (2002). The cryopreservation of the baseball player, contested between his children, generated intense press coverage and a subsequent book by a former Alcor employee alleging mishandling of remains. Alcor disputed the account. Whatever the merits, the case fixed a public image of the organization that it has not escaped.
Institutional longevity. The most serious criticism is structural rather than scandalous. Patients must be maintained for an unknown period by an organization that receives no further revenue from them. Alcor's answer is the Patient Care Trust, a segregated fund invested to cover maintenance from returns, with the operating organization legally distinct from it. The 1979 collapse of the Cryonics Society of California, in which stored bodies were found thawed after the organization ran out of money, is the field's worked example of what the structure is meant to prevent. Whether any private institution can hold that arrangement for two centuries is untested and untestable in advance.
Alcor has over a thousand members and roughly 250 patients in storage as of the mid-2020s, with growth that has been slow and approximately linear for decades. Minimum funding is $200,000 for whole-body and $80,000 for neuropreservation, with a portion allocated to the Patient Care Trust and the remainder to the cost of the procedure and standby.
The membership is not representative. It skews technical, male, American, and drawn disproportionately from the transhumanist and software communities — the same population that produced Extropianism, with which Alcor's leadership has overlapped. Notable patients include the futurist FM-2030 and the cryptographer Hal Finney. Max More, who wrote the extropian principles, led the organization from 2011 to 2020.
The Society for Cryobiology has distanced itself from cryonics for decades and at one point barred practitioners from membership. Its objection is not that low-temperature storage fails to arrest decay, which is uncontroversial physics, but that the ischemic and toxic injury sustained before and during preservation is unquantified, that no mammal has been revived from cryogenic temperature, and that describing the practice as medicine misleads the public.
Supporters make a narrower argument. The relevant threshold is information-theoretic death, formalized by Ralph Merkle: whether the structures encoding memory and personality remain inferable, not whether tissue remains alive.1 The routes from there — cell-by-cell repair by hypothetical Medical nanorobots, or scanning the preserved brain and running it as an emulation on the Substrate independence premise — and the objections to each are set out under Cryonics. Alcor's own literature endorses neither route and no timeline; critics respond that an unfalsifiable bet with an unbounded payoff is a poor guide to action, and that the resemblance to Pascal's wager is not accidental.
The developments that would most change Alcor's position are happening outside it. Vitrification and rewarming of whole mammalian organs, driven by the Organ shortage and organ-banking field rather than by cryonics, has produced a vitrified rabbit kidney that supported an animal after transplantation2 and, more recently, rat kidneys rewarmed by inductive heating of infused magnetic nanoparticles and transplanted with restored function.3 Scaling that to larger organs would supply the first direct evidence that a large vitrified mammalian structure can be recovered. Separately, progress in Connectomics toward reconstructing circuitry from preserved tissue bears on whether a preserved brain contains what the practice assumes it contains.
Neither line of work will answer the question Alcor exists to answer, which is not technical. The organization is a wager that an institution can outlast the problem it was created to survive, and the only test of that is time.
paperMerkle, R.C. "The Molecular Repair of the Brain." Cryonics, 1994.↩Cryonics is the magazine published by the organization this article describes, so the argument appears in a house venue rather than a reviewed one.
paperFahy, G.M., Wowk, B., Pagotan, R. et al. "Physical and biological aspects of renal vitrification." Organogenesis, 2009. ↩
paperHan, Z. et al. "Vitrification and nanowarming enable long-term organ cryopreservation and life-sustaining kidney transplantation in a rat model." Nature Communications, 2023.↩The organ was a rat kidney rewarmed by heating infused magnetic nanoparticles; nothing of human-organ scale has been recovered by this route.